Archive for December 2015

What is YK11, how does YK11 work

What is YK11?

(17α,20E)-17,20-[(1-methoxyethylidene)bis-(oxy)]-3-oxo-19-norpregna-4,20-diene-21-carboxylic acid methyl ester (YK11), which the myogenic differentiation of C2C12 myoblast cells is induced by the novel androgen receptor (AR) partial agonist.as well as by dihydrotestosterone (DHT).

YK11 is a selective androgen receptor modulator (SARM), which activates AR without the N/C interaction. In this study, we further investigated the mechanism by which YK11 induces myogenic differentiation of C2C12 cells. The induction of key myogenic regulatory factors (MRFs), such as myogenic differentiation factor (MyoD), myogenic factor 5 (Myf5) and myogenin, was more significant in the presence of YK11 than in the presence of DHT. YK11 treatment of C2C12 cells, but not DHT, induced the expression of follistatin (Fst), and the YK11-mediated myogenic differentiation was reversed by anti-Fst antibody.

Myogenic differentiation is in reference to the products ability to block myostatin. Myostatin inhibition has been a really popular movement since the ban of most prohormones as it looks to be a relatively unexplored area for muscle growth and fat loss. There are currently a lot of claims about mystatin inhibition, but not so much factual data on these products. YK11 will have similar affects to DHT (possibly more potent) without the negatives of DHT. What this means is that the product will most likely be suppressive and require a post cycle, but not cycle support. It also won’t have androgenic side affects like hair loss, acne, etc. The increase in follistatin caused by YK11 will act as an antagonist to mystatin (it will block myostatin) as well as the anabolic growth properties of YK11.

How does YK11 work?

In direct comparison to to LGD-4033 as the reference for assay upon animal models of anabolism and androgenicity, YK-11 demonstrated higher efficacy withing anabolic parameters and lesser androgenicity at equivalent dosages.

It induces muscle cells to make more follistatin which is a strong myostatin inhibitor. Myostatin (also known as growth differentiation factor 8, is a myokine (protein) produced by muscle cells that acts on muscle cells to inhibit myogenesis. Myogenesis is muscle cell growth and differentiation. Research through the years show that when you block myostatin, it allows for significantly more muscle mass. So in research myostatin inhibitors are researched to find cures for muscle diseases.

We expect YK11 to be more potent than SARM LGD in terms of overall growth and feel. At this time, we expect this to be the strongest SARM on the market at a regular dosing. While suppression can occur, we expect this product to have low androgenic properties and can be used by both men and women. From our experience with SARMs, we find there are less losses of on-cycle results than pro-hormones, although typically not as potent. We do expect this product to have similar results as a moderately dosed Halodrol, without the alpha-male/androgenic feelings while on it.

YK11 Dosages and Possible Suggestion

Recommended maximum dose YK11 is require dosages of 2.0-5.0mg b.i.d. in males and 0.5mg-2mg b.i.d. in females to achieve optimal effects in humans for the noted indications

Share with your friendsEmail this to someoneTweet about this on TwitterShare on Google+Share on FacebookPin on PinterestDigg thisShare on StumbleUponShare on TumblrShare on Reddit

GW-501516 – THE ULTIMATE PERFORMANCE ENHANCER

GW-501516 is a drug that acts as a PPARδ modulator. GW-501516 is a selective agonist (activator) of the PPARδ receptor. It displays high affinity (Ki = 1 nM) and potency (EC50 = 1 nM) for PPARδ with > 1000 fold selectivity over PPARα and PPARγ. GW-501516 activates the AMP-activated protein kinase and stimulates glucose uptake in skeletal muscle tissue.

GW-501516 has been demonstrated to reverse metabolic abnormalities in obese men with pre-diabetic metabolic syndrome, most likely by stimulating fatty acid oxidation. It has been proposed as a potential treatment for obesity and related conditions.

GW-501516 has also shown to dramatically increase endurance and recovery. In rats, binding of GW501516 to PPARδ recruits the co-activator PGC-1a. The PPARδ/coactivator complex in turn up regulates the expression of proteins involved in energy expenditure.

In obese rhesus monkeys, GW-501516 increased high-density lipoprotein (HDL) and lowered very-low-density lipoprotein (VLDL). The mechanism by which PPARδ agonists increase HDL appears to be a result of increased expression of the cholesterol transporter ABCA1.

GW-501516 Beneficial Uses:

GW-501516 has many benefits but has two primary uses. The most common use of GW consists of the extreme amount of endurance and recovery increase. The results with GW-501516 use regarding endurance increase are staggering. GW was banned by the WADA (World Anti Doping Association) in 2009 because it provided such a large advantage to users over their competition. GW has shown to be fast acting with drastic results. A user can expect to see an endurance increase within a few days of use. GW-501516 provides continuous increases in the VO2MAX, allowing an individual to provide maximal output during exercise, thus obtaining the name, “The Ultimate Performance Enhancer.” The common dosage for this type of result is 20 mg a day with 14 weeks of continuous use

The other main use of GW-501516 is to aid in fat loss. GW-501516 has shown to melt away fat at a rapid pace. Another strong component of GW-501516 is that it is non catabolic, meaning it allows a user to lose fat and not have to sacrifice muscle. Many people that are on a fat burning diet are sacrificing a lot of muscle. GW-501516 allows a user to hold on to much more muscle than a standard fat lass diet or other fat loss compound would allow. GW-501516 also shines when ran in conjunction with other SARMS. When stacking GW-501516 with Ostarine and S4, users can add lean muscle while still losing weight and body fat. This makes GW-501516 highly desirable for many. The most optimal dosage for fat loss is 20 mg a day but users will still be able to receive this benefit at 10 mg a day.

GW 501516 can be ran in 8-12 cycles and can also be ran in conjunction with any SARM, steroid or supplement. As with any other steroid or supplement, it should be cycled properly to avoid any possible side effects and the keep it as effective as possible.

GW-501516 Dosing Timing:

GW-501516 also has a very long half life, so it can be dosed once a day or split 12 hours apart. The most effective method of dosing is to take it in one serving, 30 minutes prior to working out. On non workout days, once a day dosing in the morning is the best method. If a split dosage is used, 10-12 hour splits are optimal.

GW-501516 Side effects:

There are constant debates and many studies arguing the potential side effects for a user. There are studies showing that GW-501516 has caused cancer in rats while other studies refute it. The ONE study that was conducted that showed this issue was deeply flawed and refuted time and time again. GW-501516 dosing was not only abused but ran at insurmountable amounts of time within this study. When ran properly, it has actually been used as a cancer treatment. There are no known side effects associated with GW use and the only need to cycle off is so that one’s body does not acclimate or desensitize to use. There is no suppression, no toxicity and no other common side effects. This makes GW even more desirable amongst the bodybuilding community.

Benefits of GW-501516:

Extreme increases in endurance and recovery
Extreme fat melting
Long Half Life Making Dosing Optimal
Lowering of Bad Cholesterol and Increasing Good Cholesterol
Minimal Side Effects
Can be ran up to 12 weeks
Stacks well with everything
Non catabolic
Excellent energy
Excellent overall sense of well-being and feeling

 

The Science of GW-501516 Fat Burning

GW-50156 regulates fat burning through a number of widespread mechanisms. GW-501516 increases glucose uptake in skeletal muscle tissue and increases muscle gene expression, especially genes involved in preferential lipid utilization. This shift changes the body’s metabolism to favor burning fat for energy instead of carbohydrates or muscle protein, potentially allowing clinical application for obese patients to lose fat effectively without experiencing muscle catabolism or the effects and satiety issues associated with low blood sugar. GW-501516 also increases muscle mass, which improved glucose tolerance and reduced fat mass accumulation even in mice fed a very high fat diet, suggesting that GW-501516 may have a protective effect against obesity.


 GW-501516 is a selective agonist (activator) of the PPARδ receptor. It displays high affinity (Ki = 1 nM) and potency (EC50 = 1 nM) for PPARδ with > 1000 fold selectivity over PPARα and PPARγ. 

In rats, binding of GW501516 to PPARδ recruits the co activator PGC-1a. The PPARδ/coactivator complex in turn up regulates the expression of proteins involved in energy expenditure. Furthermore in rats treated with GW501516, increased fatty acid metabolism in skeletal muscle and protection against diet-induced obesity and type II diabetes was observed. In obese rhesus monkeys, GW-501516 increased high-density lipoprotein (HDL) and lowered very-low-density lipoprotein (VLDL). The mechanism by which PPARδ agonists increase HDL appears to be a result of increased expression of the cholesterol transporter ABCA1.

Cholesterol Improvement

An often overlooked benefit of GW-501516 use is the ability to treat poor cholesterol. GW was originally formulated to treat people suffering from cholesterol problems and has shown to significantly increase HDL (good cholesterol) while reducing LDL (bad cholesterol).

 

Share with your friendsEmail this to someoneTweet about this on TwitterShare on Google+Share on FacebookPin on PinterestDigg thisShare on StumbleUponShare on TumblrShare on Reddit
eXTReMe Tracker